

(12) International Application Status Report

Received at International Bureau: 29 November 2011 (29.11.2011)

Information valid as of: 25 April 2013 (25.04.2013)

Report generated on: 06 March 2021 (06.03.2021)

(10) Publication number:

WO2012/073253

(43) Publication date:

07 June 2012 (07.06.2012)

(26) Publication language:

English (EN)

(21) Application Number:

PCT/IN2011/000684

(22) Filing Date:

30 September 2011 (30.09.2011)

(25) Filing language:

English (EN)

(31) Priority number(s):

2505/CHE/2010 (IN)

(31) Priority date(s):

30 September 2010 (30.09.2010)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

C12N 5/00 (2006.01); **C12N 5/09** (2010.01); **C12N 15/79** (2006.01); **A61K 48/00** (2006.01)

(71) Applicant(s):

BOOMINATHAN, Lakshmanane [IN/IN]; 49 Nattar Main Street Murungapakkam Mudaliarpet Puducherry 605 004 (IN) (*for all designated states*)

(72) Inventor(s):

BOOMINATHAN, Lakshmanane; 49 Nattar Main Street Murungapakkam Mudaliarpet Puducherry 605 004 (IN)

(54) Title (EN): THERAPEUTIC USES OF MIRNAS/COMPOUNDS THAT ACTIVATE TUMOR SUPPRESSOR GENES/ MIRNAS

(54) Title (FR): UTILISATIONS THÉRAPEUTIQUES DE MICROARN/COMPOSÉS QUI ACTIVENT LES GÈNES/ MICROARN SUPPRESSEURS DE TUMEUR

(57) Abstract:

(EN): The invention illustrates how the TA-p73 and TA-p63 could function as negative regulators of invasion, metastasis, and cancer stem cells proliferation. In particular, p53 and TA-p73/ p63 appear to up regulate the expression of tumor suppressor miRNA, tumor suppressor genes and metastasis suppressors. Further, suppressing of c-myc expression can increase the expression of tumor suppressor miRNAs/genes. Identifying small molecule compounds that simultaneously suppress oncogenes and activate tumor suppressor miRNAs/genes will aid cancer therapy.

(FR): L'invention illustre comment les TA-p73 et TA-p63 pourraient fonctionner en tant que régulateurs négatifs de l'invasion, des métastases, et de la prolifération des cellules souches du cancer. En particulier, p53 et TA-p73/p63 semblent réguler positivement l'expression de microARN suppresseur de tumeur, de gènes suppresseurs de tumeur et de suppresseurs de métastases. De plus, la suppression de l'expression de c-myc peut augmenter l'expression de microARN/gènes suppresseurs de tumeur. L'identification de composés de petites molécules qui simultanément suppriment les oncogènes et activent les microARN/gènes suppresseurs de tumeur aidera le traitement du cancer.

International search report:

Received at International Bureau: 19 March 2012 (19.03.2012) [CN]

International Report on Patentability (IPRP) Chapter II of the PCT:

Not available

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

Declarations:

Declaration of inventorship (Rules 4.17(iv) and 51bis.1(a)(iv)) for the purposes of the designation of the United States of America